Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Core Points - Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases [3] - The company will report its second quarter 2025 financial results on August 12, 2025, and will host a conference call at 8:30 am E.T. to discuss these results and provide a business update [1] - The lead program of Altimmune is pemvidutide, a GLP-1/glucagon dual receptor agonist aimed at treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD), and obesity [3] Company Information - Altimmune is engaged in the development of therapeutics specifically targeting liver and cardiometabolic diseases [3] - The company’s lead therapeutic candidate, pemvidutide, is designed to address multiple conditions related to metabolic dysfunction and alcohol use [3] - For further information, Altimmune maintains an Investor Relations website where financial results and updates can be accessed [1][2]